Answers are grounded in this paper and cite their sources.
Our findings provide insights into the scope and regulation of CEACAM5 expression in prostate cancer and strong support for clinical studies of labetuzumab govitecan for NEPC.
No takes yet. Share an insight, caveat, or question.
DeLucia et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: